Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.56 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$24.98M
Enterprise Value-$38.25M
Total Cash (Recent Filing)$74.27M
Total Debt (Recent Filing)$11.57M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 20, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding40,830,353
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.37
Price to Sales (P/S)3.18
P/FCF Ratio-1.60
Enterprise Value/Market Cap-1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$4.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt-to-equity (~0.14) gives the company durable financial flexibility to fund R&D and operations without immediate pressure from interest or near-term maturities. This reduces short-term refinancing risk and supports pursuing clinical programs while losses persist.
Positive Phase 1 Safety SignalA well-tolerated SAD readout with dose-dependent pharmacology materially de-risks the VTP-1000 program over the coming months. Durable clinical progress supports continued development, potential partner interest, and a clearer regulatory path for an antigen-specific celiac therapy.
Multiple Funding/revenue ChannelsA diversified mix of product revenue, collaborations, licensing, milestone payments and grants reduces reliance on a single cash source. Structurally this supports multiple non-dilutive funding options and partnership-led development, important during prolonged clinical stages.
Bears Say
No TTM Revenue And Large LossesAbsence of trailing revenue combined with substantial recurring losses indicates limited internal ability to self-fund operations. Over months this heightens dependence on external capital, increases dilution risk, and signals weak near-term earnings visibility for sustainable operations.
Sustained Cash BurnConsistent negative operating and free cash flow points to ongoing consumption of cash to support R&D and SG&A. Persisting cash burn raises structural financing needs, may constrain program funding or commercialization investments, and elevates pressure to raise capital.
Nasdaq Minimum Bid-price Non-compliance RiskA formal Nasdaq non-compliance notice creates a material corporate governance and access-to-capital risk. Potential delisting or a reverse split can affect liquidity, institutional interest, and ability to raise funds or execute partnerships over the medium term.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.56 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $24.98M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Mar 20, 2026 which is in 16 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Nov 07, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.395 by $0.035.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.35.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,830,353 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.395. Following the earnings report the stock price went down -10.084%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Barinthus Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (426.32% Upside)
$4.00 (426.32% Upside)
Blogger Sentiment
Bullish
BRNS Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.13%
12-Months-Change
Fundamentals
Return on Equity
-62.30%
Trailing 12-Months
Asset Growth
-42.13%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$4.00
▲(426.32% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
0.19%
Insiders
0.03% Mutual Funds
18.29% Other Institutional Investors
81.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---